» Articles » PMID: 33112501

Increased Expression of REV7 in Small Cell Lung Carcinomas and Its Association with Tumor Cell Survival and Proliferation

Overview
Journal Pathol Int
Specialty Pathology
Date 2020 Oct 28
PMID 33112501
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

REV7 is involved in multiple biological processes including DNA damage tolerance, cell cycle regulation and gene expression, and is an accessory subunit of the mutation-prone DNA polymerase ζ. It has been reported that REV7 expression is associated with poor prognosis in several human cancers. The aim of this study is to investigate the significance of REV7 in lung carcinogenesis. Immunohistochemical analyses of surgically resected lung cancer specimens revealed that REV7 shows an increased expression in small cell lung carcinomas (SCLCs) when compared with other histological types of lung carcinoma. Association between REV7 expression levels and clinicopathological factors was investigated using SCLC cases with or without surgical resection. Our analyses revealed that high REV7 expression significantly correlated with tumor cell proliferation, assessed by Ki-67 labeling indices, and was negatively associated with distant metastasis and extensive-stage disease. No significant association was detected between REV7 expression and other factors, including prognosis or response to chemoradiotherapy in SCLC. Increase in REV7 expression in SCLC was confirmed using SCLC cell lines. In addition, siRNA-mediated depletion of REV7 activated the apoptotic pathway and suppressed cell growth in SCLC cells. These results suggest that REV7 plays an important role in tumor cell survival and proliferation in SCLC.

Citing Articles

REV7: a small but mighty regulator of genome maintenance and cancer development.

Maggs L, McVey M Front Oncol. 2025; 14:1516165.

PMID: 39839778 PMC: 11747621. DOI: 10.3389/fonc.2024.1516165.


The Immunohistochemical Expression of REV-7 in Various Human Cancer Pathology Specimens: A Systematic Review.

Spinos T, Goutas D, Driva T, Zografos E, Gakiopoulou C, Agrogiannis G Cureus. 2024; 16(1):e52542.

PMID: 38371007 PMC: 10874486. DOI: 10.7759/cureus.52542.


Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.

Spinos T, Zografos E, Koutsoukos K, Zagouri F, Kosmas C, Driva T Int Urol Nephrol. 2024; 56(6):1887-1898.

PMID: 38285100 PMC: 11090952. DOI: 10.1007/s11255-023-03933-2.


REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response.

Tamaki A, Kato T, Sakurai Y, Sato K, Adachi K, Tadehara M Cancer Sci. 2023; 115(2):660-671.

PMID: 38130032 PMC: 10859597. DOI: 10.1111/cas.16044.


REV7 in Cancer Biology and Management.

Murakumo Y, Sakurai Y, Kato T, Hashimoto H, Ichinoe M Cancers (Basel). 2023; 15(6).

PMID: 36980607 PMC: 10046837. DOI: 10.3390/cancers15061721.